Although essential for cardiovascular therapy,the pleiotropic effects of statins on ischemic stroke lack clinical evidence.This study examined the effects of statins beyond low-density lipoprotein cholesterol(LDL-C)le...Although essential for cardiovascular therapy,the pleiotropic effects of statins on ischemic stroke lack clinical evidence.This study examined the effects of statins beyond low-density lipoprotein cholesterol(LDL-C)levels on mortality and stroke severity.A total of 825,874 patients with ischemic stroke were included in this study,of whom 125,650 statin users were 1:1 matched with non-users based on their LDL-C levels(±0.05 mmol/L),forming the LDL-C-matched cohort.Associations between preceding statin treatment,in-hospital mortality,and stroke severity(National Institutes of Health Stroke Scale scoreR16)were estimated by multivariate and conditional logistic regression models in overall cohort and LDL-C-matched cohort,respectively.展开更多
基金supported by grants fromthe National Key R&D Programof China(grant numbers 2022YFC2504900 and 2022YFC2504902)Beijing Natural Science Foundation(grant number Z200016)the National Natural Science Foundation of China(grant numbers 82101360 and 82171270).
文摘Although essential for cardiovascular therapy,the pleiotropic effects of statins on ischemic stroke lack clinical evidence.This study examined the effects of statins beyond low-density lipoprotein cholesterol(LDL-C)levels on mortality and stroke severity.A total of 825,874 patients with ischemic stroke were included in this study,of whom 125,650 statin users were 1:1 matched with non-users based on their LDL-C levels(±0.05 mmol/L),forming the LDL-C-matched cohort.Associations between preceding statin treatment,in-hospital mortality,and stroke severity(National Institutes of Health Stroke Scale scoreR16)were estimated by multivariate and conditional logistic regression models in overall cohort and LDL-C-matched cohort,respectively.
基金supported by the National Natural Science Foundation of China(81870905 and U20A20358)the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences(2019-I2M-5-029)the Capital's Funds for Health Improvement and Research(2020-1-2041).